Rosemont to expand into Europe and US

Rosemont Pharmaceuticals has targeted the US and European markets for oral liquid drugs.

The Yorkshire-based company was sold this week by Savient for 93 million pounds to the company’s managing director and financial director, who received backing from Close Brothers Private Equity Group (CBPE).

With over 90 liquid formulations of drugs for various treatment indications, the company has said the US market for oral liquid drugs is “untapped”.

John Blythe, Rosemont’s managing director, told the Yorkshire Post: “We aim to continue to develop the UK market as we have done over the last 40 years and also expand our operation into continental Europe and the US.”

“We still believe if there’s a market for oral liquid medication in the UK there’s the same market for these oral liquid medications in the rest of the world,” he added.

Sean Dinning, a CBPE partner, commented: “The company operates in a clear, growing niche and has excellent opportunities to develop its range of products and to sell internationally.”

Rosemont produces a variety of pharmaceutical products designed for patients in cases where other forms of drug delivery, like injection, for instance, are deemed to be unsuitable.

Its former parent company, Savient, sold Rosemont as it said it wished to focus on developing Puricase, a gout treatment.

Leeds-based Rosemont employs approximately 170 people.

© Adfero Ltd